Literature DB >> 25957185

Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

George Rodrigues1, Hak Choy2, Jeffrey Bradley3, Kenneth E Rosenzweig4, Jeffrey Bogart5, Walter J Curran6, Elizabeth Gore7, Corey Langer8, Alexander V Louie9, Stephen Lutz10, Mitchell Machtay11, Varun Puri12, Maria Werner-Wasik13, Gregory M M Videtic14.   

Abstract

PURPOSE: To provide guidance to physicians and patients with regard to the use of adjuvant external beam radiation therapy (RT) in locally advanced non-small cell lung cancer (LA NSCLC) based on available medical evidence complemented by consensus-based expert opinion. METHODS AND MATERIALS: A panel authorized by the American Society for Radiation Oncology (ASTRO) Board of Directors and Guidelines Subcommittee conducted 2 systematic reviews on the following topics: (1) indications for postoperative adjuvant RT and (2) indications for preoperative neoadjuvant RT. Practice guideline recommendations were approved using an a priori-defined consensus-building methodology supported by ASTRO and approved tools for the grading of evidence quality and the strength of guideline recommendations.
RESULTS: For patients who have undergone surgical resection, high-level evidence suggests that use of postoperative RT does not influence survival, but optimizes local control for patients with N2 involvement, and its use in the setting of positive margins or gross primary/nodal residual disease is recommended. No high-level evidence exists for the routine use of preoperative induction chemoradiation therapy; however, modern surgical series and a post-hoc Intergroup 0139 clinical trial analysis suggest that a survival benefit may exist if patients are properly selected and surgical techniques/postoperative care is optimized.
CONCLUSIONS: A consensus and evidence-based clinical practice guideline for the adjuvant radiotherapeutic management of LA NSCLC has been created addressing 2 important questions.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25957185     DOI: 10.1016/j.prro.2015.02.013

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  16 in total

1.  Postoperative radiotherapy and lung cancer in stage III: helpful or harmful.

Authors:  Francesco Fiorica
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy.

Authors:  Mark R Waddle; Stephen Ko; Margaret M Johnson; Yanyan Lou; Robert C Miller; Anna C Harrell; Daniel M Trifiletti
Journal:  Transl Lung Cancer Res       Date:  2018-04

3.  Tri-modality treatment in N2 stage IIIa non-small cell lung cancer: proper sequence remains unknown.

Authors:  Ze-Rui Zhao; Calvin S H Ng
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Optimal sequencing of adjuvant chemotherapy and radiation therapy in resected non-small cell lung cancer with pathological N2 disease.

Authors:  George Rodrigues
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

5.  Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.

Authors:  J Agulnik; G Kasymjanova; C Pepe; M Hurry; R N Walton; L Sakr; V Cohen; M Lecavalier; D Small
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

Review 6.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

7.  [Application and interpretation of the R classification for lung cancer : Results of a survey of certified lung cancer centers].

Authors:  H Hoffmann; K Junker; C Kugler; P A Schnabel; A Warth
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

8.  Prognostic analysis of the bronchoplastic and broncho-arterioplastic lobectomy of non-small cell lung cancers-10-year experiences of 161 patients.

Authors:  Li-Lan Zhao; Fang-Yu Zhou; Chen-Yang Dai; Yi-Jiu Ren; Ge-Ning Jiang; Ke Fei; Chang Chen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 9.  Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer.

Authors:  Mikel Rico; Maribel Martínez; Maitane Rodríguez; Lombardo Rosas; Andrea Barco; Enrique Martínez
Journal:  J Clin Transl Res       Date:  2021-04-22

10.  Differential outcomes of residual disease in surgically-resected non-small cell lung cancer and the importance of guideline-concordant adjuvant therapy.

Authors:  Dustin K Lieu; Li Ding; Elizabeth A David; Sean C Wightman; Scott M Atay; P Michael McFadden; Anthony W Kim
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.